Company intelligence / Profile preview
ZWI Therapeutics
Watertown, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
ZWI Therapeutics has demonstrated preclinical proof-of-concept with its lead uricase-polycarboxybetaine conjugate (ZWI‑001) for severe gout/hyperuricemia. The company has received FDA guidance via an INTERACT meeting on CMC, non-clinical, and clinical plans and aims to file an IND soon. Its proprietary polymer platform shows promise in reducing the immunogenicity of protein therapeutics compared to PEGylation while maintaining favorable pharmacokinetics.
- Therapeutic areas
- RheumatologyImmunology
- Modalities
- Protein therapeutics (including uricase conjugates)Polymer-drug conjugates (using polycarboxybetaine)Potential applications in lipid nanoparticles and hydrogels
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major partnerships publicly disclosed as of latest funding round.
Beyond the preview
Go deeper on ZWI Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZWI Therapeutics.